Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit

Dimpy Modi¹, Saifur R Chowdhury^{1

2}, Syed Mahamad¹, Hayley Modi^{1

3}, Douglas B Cines⁴, Cindy E Neunert⁵, Hanny Al-Samkari⁶, Nichola Cooper⁷, Guillaume Moulis⁸, Charlotte Cunningham-Rundles⁹, Howard A Liebman¹⁰, James B Bussel¹¹, Vicky R Breakey¹², Ishac Nazy^{1

3

13}, Donald M Arnold^{1

13}

Affiliations

¹ Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
² Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada.
³ Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
⁴ Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
⁵ Columbia University Irving Medical Center, New York, New York, United States.
⁶ Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, United States.
⁷ Hammersmith Hospital, Imperial College, London, United Kingdom.
⁸ Department of Internal Medicine, Toulouse University Hospital, Toulouse, France.
⁹ Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, United States.
¹⁰ University of Southern California-Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, United States.
¹¹ Platelet Research & Treatment Program Weill, Cornell Medicine, New York, United States.
¹² McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada.
¹³ Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

PMID: 39719150
PMCID: PMC12373449
DOI: 10.1055/a-2508-1112

Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit

Dimpy Modi et al. Thromb Haemost. 2025 Sep.

. 2025 Sep;125(9):923-932.

doi: 10.1055/a-2508-1112. Epub 2024 Dec 24.

Authors

Affiliations

¹ Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
² Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada.
³ Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
⁴ Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
⁵ Columbia University Irving Medical Center, New York, New York, United States.
⁶ Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, United States.
⁷ Hammersmith Hospital, Imperial College, London, United Kingdom.
⁸ Department of Internal Medicine, Toulouse University Hospital, Toulouse, France.
⁹ Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, United States.
¹⁰ University of Southern California-Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, United States.
¹¹ Platelet Research & Treatment Program Weill, Cornell Medicine, New York, United States.
¹² McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada.
¹³ Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

PMID: 39719150
PMCID: PMC12373449
DOI: 10.1055/a-2508-1112

Abstract

The McMaster Immune Thrombocytopenia (ITP) Summit, held on October 27, 2023, was an educational seminar from leading experts in immune thrombocytopenia and related disorders geared toward hematologists, internists, immunologists, and clinical and translational scientists. The focus of the Summit was to review the mechanisms, diagnosis, and treatment of primary versus secondary ITP. Specific objectives were to describe the unique features of secondary ITP, and to review its mechanisms in the context of autoimmune disease and infection. The key messages in this Summit were: (1) ITP is a heterogeneous disease, and genetic and immunologic insights may help classify patient subtypes; (2) exploring the autoimmune mechanisms and their association with hypogammaglobulinemia in patients with secondary ITP could improve our understanding of ITP and its subtypes; (3) investigating the mechanisms of ITP in the context of infections caused by viruses such as CMV, HIV, dengue, and hepatitis C, or bacteria such as H. pylori, or vaccinations could provide insight into the causes of ITP. A better understanding of secondary ITP could help elucidate the pathogenesis of ITP.

The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

PubMed Disclaimer

Conflict of interest statement

D.C. reports consulting fees from Novartis and Sanofi. D.C. also serves on a Data Safety Monitoring Board or Advisory Board for Novartis and Sanofi. C.N. has received author royalties from UpToDate. Consulting fees were received from ArgenX, Novartis, Sobi, Sanofi, and Genzyme, while an ongoing consultancy exists with Janssen. Honoraria were received from Sanofi. Payments for expert testimony were received from the U.S. Department of Defense Vaccine Program and Stein Mitchell Beato & Missner LLP. Travel support was received from Sanofi for ISTH 2024. Unpaid roles include being a medical advisor for ITP Australia and The UK ITP Support Association, and a committee member with ASH Committee on Quality, ISTH Meeting Planning Committee 2025, and a chair on the ASPHO review course. H.A. received grants or contracts from Agios, Amgen, Novartis, Vaderis, and Sobi to their institution. Consulting payments were received from Amgen, Novartis, Alnylam, Agios, Argenx, Alpine, Sobi, and Pharmacosmos. N.C. disclosed participation on a data safety monitoring board or advisory board, and payment for honoraria for lectures, presentations, speakers, bureaus, manuscript writing, or educational events from Amgen, Novartis, Griffols, and Sobi. G.M. disclosed support from McMaster University related to the present manuscript. G.M. has received grants or contracts from Amgen, Argenx, Grifols, Novartis, and Sanofi, and consulting fees from Argenx, Grifols, Novartis, Sanofi, Alpine, and Amgen, along with payments from Amgen, Grifols, and Novartis. Support for attending meetings was provided by Amgen, Grifols, and Novartis. C.C.R. disclosed a consultancy role with Pharming, award committee role with Grifols, and data safety monitoring board role with Otsuka since the initial planning of this manuscript. C.C.R. has received grants or contracts from X4 and NIH USIDNET, and serves on a steering committee for NIH USIDNET. Consulting fees were received from Pharming and X4. C.C.R. also attended meetings and events sponsored by the CIS Summer School 2024, CIS National Meeting 2024, and the California Allergy Immunology Society 2024. Patents are planned, issued, or pending for the use of BTK in inflammatory diseases in CVID. C.C.R. holds a leadership role in the Royal PID group in New York City. H.A.L. has received grants or contracts from Sanofi, and consulting fees from Sanofi, Novartis, and Alpine Immune Sciences. J.B.B. has received consulting fees from Amgen, Novartis, SOBI, UCB, Argenx, Janssen, and RallyBio. D.M.A. declares receiving grants or contract support from the Canadian Institutes of Health Research, Rigel, and Alpine Immune Sciences (all related to ITP), royalties or licenses from UpToDate, and consulting fees from Novartis, Rigel, Amgen, Medison, Sobi, and Argenx (all related to ITP). D.M.A. also serves as an unpaid medical advisor for the Platelet Disorders Support Association. D.M., S.R.C., S.M., H.M., V.R.B., and I.N. declare that they have no conflicts of interest.

References

1. Li Q, Marcoux G, Hu Y et al. Autoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP) Autoimmun Rev. 2024;23(12):103677. - PubMed
1. Zhang W, Nardi M A, Borkowsky W, Li Z, Karpatkin S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood. 2009;113(17):4086–4093. - PMC - PubMed
1. Wright J F, Blanchette V S, Wang H et al. Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP) Br J Haematol. 1996;95(01):145–152. - PubMed
1. Cines D B, Bussel J B, Liebman H A, Luning Prak E T. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511–6521. - PMC - PubMed
1. Moulis G, Palmaro A, Montastruc J L, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–3315. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Georg Thieme Verlag Stuttgart, New York
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit

Affiliations

Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources